Company profile
Profile of Consun Pharmaceutical Group
Consun Pharmaceutical Group (Stock Code:01681.HK) is a modern pharmaceutical enterprise that integrates R&D, production and marketing. It was founded in 1997 and listed on the Hong Kong Stock Exchange in 2013. It owns subsidiaries including Guangzhou Consun Pharmaceutical Co. Ltd, Consun Pharmaceutical (Inner Mongolia) Co. Ltd, Consun Pharmaceutical (Horgos) Co. Ltd, Guangxi Yulin Pharmaceutical Group Co. Ltd, etc. and operates pharmaceutical brands including “Consun”, “Yulin” etc.,with more than 3,000 employees.
Consun offers a portfolio of 143 medicines, including 62 Chinese patent medicines and 81 chemical drugs. Among them, 33 medicines are on the National Essential Drugs List, 71 medicines are on the National Drug Reimbursement List (2024 Edition). Our flagship product, Uremic Clearance Granule, is the first modern Chinese patent medicine in China’s nephrology field to complete rigorous Randomized Controlled Trial (RCT) clinical validation and comprehensive evidence-based evaluation. Renowned for its proven clinical value, it has consistently held the leading position in the Chinese patent medicine market for nephrology for years.
Consun provides integrated, end-to-end nephrology solutions through the synergy of Traditional Chinese and Western medicine. Beyond the core strength in renal care, Consun also deepens its expertise in medical imaging, gynecology & pediatrics, and OTC healthcare. Among them are a number of core products, including Yishen Huashi Granule, Gadopentetate Dimeglumine Injection, Iron Dextran Oral Solution, Zheng Gu Shui, Shiduqing Capsule and Jigucao Capsule,etc., to meet the diverse health needs of patients.
With innovation as its core growth engine, Consun has established a scientific and highly efficient R&D system and innovation mechanism. This R&D engine is powered by a dedicated team of over 100 professionals, with more than 50% holding doctoral or master’s degrees. It has secured over 50 patents. Consun has established accredited platforms including a Postdoctoral Research Workstation, a Provincial Engineering Technology Research Center, a Technology Innovation Center, and Corporate R&D Centers etc. Consun has also deepened collaboration with leading universities and research institutes, including the Peking University Health Science Center, China Academy of Chinese Medical Sciences, Beijing University of Chinese Medicine, Hong Kong Baptist University, Macau University of Science and Technology, Shenzhen Institute of Advanced Technology of Chinese Academy of Sciences, Zhongshan Hospital of Fudan University, and Zhongda Hospital of Southeast University, etc. to accelerate the translation of research into novel therapies.
Consun has strategically established a synergistic north-south production network, with bases located in Guangzhou (Guangdong), Tongliao (Inner Mongolia), Yulin (Guangxi), and Horgos (Xinjiang). This geographically diversified layout ensures the efficient and stable supply of high-quality pharmaceutical products. Consun has cultivated a specialized in-house academic promotion team of more than 1,500 professionals, supported by a comprehensive nationwide sales network. By leveraging academic collaboration as a bridge, this team effectively disseminates the scientific value of our medicines. Concurrently, Consun is expanding into overseas markets and has commercialized its products in over 30 countries and regions, steadily advancing its internationalization strategy.
“Guided by Integrity, Where Ethics and Profit Thrive Together” — this is the business philosophy Consun upholds. Consun takes the well-being of humanity as its core mission and actively fulfills its corporate responsibilities. Its philanthropic efforts extend to poverty alleviation, disaster relief, supporting education (including student assistance and teacher development), and advancing the development of the pharmaceutical industry.
A testament to its outstanding market performance and deep commitment to social responsibility, Consun has earned consistent market and industry recognition: It was named to the “Forbes Asia's 200 Best Under A Billion" list in 2023, maintained its 22nd position on the "China Top 100 Traditional Chinese Medicine Enterprises" list in 2024, and ranked 87th on the "2024 Top 100 Chinese Pharmaceutical Companies" list with a brand value of RMB 14.755 billion.
Guided by its mission of “Inheriting Wisdom, Innovating for Health; Trusted Medicine for the People,” Consun will persevere with unwavering commitment and strive resolutely to fulfill its development vision of “To be a Global Leader in Nephrology and a Pioneer in Specialized Medicine,” with the ultimate goal of safeguarding human health.
